Fujifilm (TSE:4901) said yesterday that it opened a new life science strategic business office in Cambridge, Mass., hoping the new location will help the company “cultivate and foster relationships with pharmaceutical and biotechnology business, and the technology communities” in the area.
The Tokyo-based company said that the opening of the new office is part of the company’s overall commitment to life sciences, and follows a number of strategic collaborations the company has entered into over the past few months.
Fujifilm said that it recently established a Fujifilm Fellowship Fund with Harvard Medical School to support Ph.D. candidates focused on therapeutic innovation, sponsored research at the Massachusetts Institute of Technology’s Koch Institute for Integrative Cancer Research and invested into Lyndra Therapeutics’ Series B round to support Phase II clinical trials of its therapies.
“Our goal is to connect, invest and co-innovate with academic, institutional, commercial and government partners with the overall objectives to accelerate translational medicine, and improve patient care and quality of life,” Fujifilm Irvine Scientific prez & CEO Yutaka Yamaguchi said in a press release.
“Over the past few years, Fujifilm has made significant investments in the life science business including sponsored research, licensing, business partnerships and acquisitions. Our new location in Cambridge provides an ideal environment to foster collaboration and bring business and technology together,” Fujifilm corporate new biz development division perz Bruce Novich said in a prepared statement.